Bliss GVS Pharma Limited
NSE: BLISSGVSMarket Closed • NSE
Day range
52 week range
Bliss GVS Pharma Limited closed at INR652.00 (-0.35%) on volume 0.39x its 20-day average, trading 11.88% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved +52.9% QoQ
2026-07-08
DIVIDEND Announced
Dividend - Re 1 Per Share
2026-02-18
DIVIDEND Announced
Interim Dividend - Re 0.50 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
High Cash Flow Conversion: CFO/PAT averaged 1.2x over last 3 years
Risks
Elevated Leverage Burden: Debt-to-Equity stands at 1.77x
Stretched Valuation: Trading at a high P/E multiple of 51.7x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 08 Jul 2026 | Dividend | ₹1.00 / share | — | 08 Jul 2026 |
| 18 Feb 2026 | Dividend | ₹0.50 / share | — | 18 Feb 2026 |
| 24 Jul 2025 | Dividend | ₹0.50 / share | — | 24 Jul 2025 |
| — | Dividend | ₹0.50 / share | — | 18 Jul 2024 |
| — | Dividend | ₹0.50 / share | — | 12 Jul 2023 |
| — | Dividend | ₹0.50 / share | — | 20 Jun 2022 |
| — | Dividend | ₹0.50 / share | — | 13 Sept 2021 |
| — | Dividend | ₹0.50 / share | — | 17 Sept 2020 |
| — | Dividend | ₹1.00 / share | — | 12 Sept 2019 |
| — | Dividend | ₹1.00 / share | — | 14 Aug 2018 |
| — | Dividend | ₹0.60 / share | — | 18 Sept 2017 |
| — | Dividend | ₹0.50 / share | — | 06 Sept 2016 |
| — | Dividend | ₹0.50 / share | — | 08 Sept 2015 |
| 25 Feb 2015 | Dividend | ₹0.20 / share | — | 24 Feb 2015 |
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, shampoo, soaps, sprays, and vaginal washes. In addition, it offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials, anti-microbials, anti-migraines, anti-oxidants, anti-protozoals, anti-pyretics, anti-septics, anti-spasmodics, anti-ulcers, and anti-ulcerants; cough syrups and nasal decongestants; and products for erectile dysfunction, laryngitis, and pharyngitis. Further, it provides and anti-dandruff shampoos, appetizers, hand sanitizers, health and nutritional supplements, insecticides, mosquito repellants, moisturizers, prickly heat powders, skin lightening lotions, vaginal contraceptives, vaginal hygiene products, and vitamin supplements; and amino acid preparations, iron tonics, antitussives, appetite stimulants, anti-allergics, body supplements, ear wax solvents, and oral rehydration products. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.
IndiaHealthcare
Is Bliss GVS Pharma Limited Shariah compliant?
Bliss GVS Pharma Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.31%) complies with AAOIFI threshold (≤ 33%).
What is Bliss GVS Pharma Limited's current valuation relative to peers?
Bliss GVS Pharma Limited trades at a P/E of 51.7x compared to the sector median of 37x, and a Price-to-Book of 5.8x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 1.77x. Interest coverage is 42.9x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 2.5% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.